pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

Celltrion Inc

updated 2mo ago

Celltrion, Inc. is a biopharmaceutical company headquartered in Incheon, South Korea. Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines developed by Celltrion. Celltrion's founder, Seo Jung-jin, is the richest person in South Korea. Seo Jung-jin, its founder was awarded the 2021 EY World Entrepreneur Of The Year.

community read0 votes

🐶 often sniffed alongside

top 8
  • tagApproval20 co-mentions · 10 sources
  • drugAVTOZMA8 co-mentions · 4 sources
  • drugOSENVELT6 co-mentions · 3 sources
  • drugtocilizumab4 co-mentions · 4 sources
  • drugACTEMRA4 co-mentions · 4 sources
  • drugOMLYCLO4 co-mentions · 2 sources
  • drugdenosumab3 co-mentions · 3 sources
  • drugXgeva3 co-mentions · 3 sources
pipeline
12
marketed
5
phase 3
1
catalysts ytd
2
approvals ytd
2
recalls ytd
0

Pipeline(12)

pipeline depth12 products
Preclinical: 2Phase 1: 1Phase 2: 1Phase 3: 1Marketed: 5Unknown: 2
2Preclinical1Phase 11Phase 21Phase 35Marketed2Unknown
Marketed
AVTOZMA
Marketed
EYDENZELT
Marketed
OSENVELT
Marketed
STEQEYMA
Marketed
YUFLYMA
Phase 3
ocrelizumab biosimilar
Relapsing Remitting Multiple Sclerosis (RRMS)
Phase 2
regdanvimab
Coronavirus Disease 2019 (COVID-19)
Phase 1
PBXCT-02
Bladder Cancer
Preclinical
CTP-45
Autoimmune Disorders
Preclinical
CTP-68
Autoimmune Disorders
drug
OMLYCLO
drug
TRUXIMA

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →
🐶 Hiring Signal
No open roles indexed yet — view Celltrion Inc jobs →

News

no news has mentioned this company yet
identifiers
source
globaldata
top tags
Immunology2Infectious Disease1NSCLC1Oncology1
mentioned in
0news items
entity-linker matched
Data sources
openFDA
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?